INTRODUCTION: CD39/NTPDase-1 is a cell surface enzyme expressed on leukocytes and endothelial cells that metabolizes ATP to ADP and AMP. CD39 is expressed on numerous different types of normal leukocytes, but details of its expression have not been determined previously. METHODS: We examined CD39 expression and activity in leukocytes isolated from healthy volunteers. Expression of CD39 on leukocytes was measured by FACS and activity of CD39 in lymphocytes and neutrophils was determined by an enzymatic radio-TLC assay. RESULTS: We established that CD39 is expressed on neutrophils, lymphocytes, and monocytes. The enzyme is found on >90% of monocytes, neutrophils, and B-lymphocytes, and 6% of T-lymphocytes and natural killer cells. Per cell density of expression varied, with the highest expression on monocytes and B-lymphocytes. ATPase and ADPase activities were highest on B-lymphocytes, lower on neutrophils, lowest on T-lymphocytes. The ratio of ADPase:ATPase activity was 1.8 for neutrophils and B-lymphocytes and 1.4 for T-lymphocytes. Hypertensive volunteers had lower levels of CD39 on their T-lymphocytes and NK cells. No correlation between age, gender, ethnic background, or cholesterol level and CD39 expression was observed. CONCLUSIONS: We conclude that CD39 activity and expression are present to varying degrees on all leukocytes types examined. Differences between leukocyte types should be considered when examining CD39 in disease states.
INTRODUCTION:CD39/NTPDase-1 is a cell surface enzyme expressed on leukocytes and endothelial cells that metabolizes ATP to ADP and AMP. CD39 is expressed on numerous different types of normal leukocytes, but details of its expression have not been determined previously. METHODS: We examined CD39 expression and activity in leukocytes isolated from healthy volunteers. Expression of CD39 on leukocytes was measured by FACS and activity of CD39 in lymphocytes and neutrophils was determined by an enzymatic radio-TLC assay. RESULTS: We established that CD39 is expressed on neutrophils, lymphocytes, and monocytes. The enzyme is found on >90% of monocytes, neutrophils, and B-lymphocytes, and 6% of T-lymphocytes and natural killer cells. Per cell density of expression varied, with the highest expression on monocytes and B-lymphocytes. ATPase and ADPase activities were highest on B-lymphocytes, lower on neutrophils, lowest on T-lymphocytes. The ratio of ADPase:ATPase activity was 1.8 for neutrophils and B-lymphocytes and 1.4 for T-lymphocytes. Hypertensive volunteers had lower levels of CD39 on their T-lymphocytes and NK cells. No correlation between age, gender, ethnic background, or cholesterol level and CD39 expression was observed. CONCLUSIONS: We conclude that CD39 activity and expression are present to varying degrees on all leukocytes types examined. Differences between leukocyte types should be considered when examining CD39 in disease states.
Authors: Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger Journal: Science Date: 2006-12-15 Impact factor: 47.728
Authors: Daniela B R Leal; Cristiane A Streher; Claudia de M Bertoncheli; Luiz F D Carli; Claudio A M Leal; José E P da Silva; Vera M Morsch; Maria R C Schetinger Journal: Biochim Biophys Acta Date: 2005-11-17
Authors: F Davi; H J Delecluse; P Guiet; J Gabarre; A Fayon; O Gentilhomme; P Felman; C Bayle; F Berger; J Audouin; P A Bryon; J Diebold; M Raphaël Journal: J Clin Oncol Date: 1998-12 Impact factor: 44.544
Authors: Aaron J Marcus; M Johan Broekman; Joan H F Drosopoulos; Kim E Olson; Naziba Islam; David J Pinsky; Roberto Levi Journal: Semin Thromb Hemost Date: 2005-04 Impact factor: 4.180
Authors: E Kaczmarek; K Koziak; J Sévigny; J B Siegel; J Anrather; A R Beaudoin; F H Bach; S C Robson Journal: J Biol Chem Date: 1996-12-20 Impact factor: 5.157
Authors: Karen M Dwyer; Silvia Deaglio; Wenda Gao; David Friedman; Terry B Strom; Simon C Robson Journal: Purinergic Signal Date: 2007-02-06 Impact factor: 3.765
Authors: Dianne Pulte; Richard R Furman; M Johan Broekman; Joan H F Drosopoulos; Harold S Ballard; Kim E Olson; Jorge R Kizer; Aaron J Marcus Journal: Clin Lymphoma Myeloma Leuk Date: 2011-08
Authors: Ana Paula Vieira; Maria Ângela Bianconcini Trindade; Carla Pagliari; João Avancini; Neusa Yurico Sakai-Valente; Alberto José da Silva Duarte; Gil Benard Journal: Am J Trop Med Hyg Date: 2016-02-22 Impact factor: 2.345
Authors: Roman Covarrubias; Elena Chepurko; Adam Reynolds; Zachary M Huttinger; Ryan Huttinger; Katherine Stanfill; Debra G Wheeler; Tatiana Novitskaya; Simon C Robson; Karen M Dwyer; Peter J Cowan; Richard J Gumina Journal: Arterioscler Thromb Vasc Biol Date: 2016-07-14 Impact factor: 8.311
Authors: Megha Makam; Daisy Diaz; Julie Laval; Yael Gernez; Carol K Conrad; Colleen E Dunn; Zoe A Davies; Richard B Moss; Leonore A Herzenberg; Leonard A Herzenberg; Rabindra Tirouvanziam Journal: Proc Natl Acad Sci U S A Date: 2009-03-17 Impact factor: 11.205
Authors: Matthew C Hyman; Danica Petrovic-Djergovic; Scott H Visovatti; Hui Liao; Sunitha Yanamadala; Diane Bouïs; Enming J Su; Daniel A Lawrence; M Johan Broekman; Aaron J Marcus; David J Pinsky Journal: J Clin Invest Date: 2009-04-20 Impact factor: 14.808